

**TREATMENT FOR HER2-POSITIVE METASTATIC  
SALES AT EX-MANUFACTURER P  
U.S. DOLLARS BY PRODUCT, INCLUDING  
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
Herceptin®	\$481,929,627	\$486,715,580	\$483,299,055	\$486,184,532	\$494,688,423
Ixemptra®	\$15,861,022	\$14,435,723	\$13,488,772	\$12,738,028	\$10,995,764
Kadcyla® <sup>1</sup>		\$14,328,948	\$63,999,957	\$78,256,141	\$82,852,340
Perjeta®	\$34,208,377	\$43,543,924	\$49,544,835	\$52,681,394	\$88,655,837
Tykerb®	\$31,138,049	\$29,985,339	\$26,126,981	\$24,222,882	\$22,848,420
Xeloda®	\$181,756,871	\$176,843,700	\$188,358,662	\$188,073,550	\$198,774,706
Total	\$744,893,946	\$765,853,214	\$824,818,262	\$842,156,527	\$898,815,490
Herceptin®	64.7%	63.6%	58.6%	57.7%	55.0%
Ixemptra®	2.1%	1.9%	1.6%	1.5%	1.2%
Kadcyla®		1.9%	7.8%	9.3%	9.2%
Perjeta®	4.6%	5.7%	6.0%	6.3%	9.9%
Tykerb®	4.2%	3.9%	3.2%	2.9%	2.5%
Xeloda®	24.4%	23.1%	22.8%	22.3%	22.1%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

Notes & Sources:

<sup>1</sup> Annual Kadcyla® sales totaled \$239.4 million in 2013, during the first ten months in the marketplace. Between the  
over \$240.3 million in gross sales of Kadcyla®.

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with  
chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g.  
(These assertions and sources can be found in the report.)

Includes brand and generic values.

Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'

Ixemptra® includes brand IXEMPRA 10/2007 BMO, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'

Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified

Values reflect field 'Sales \$'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.